Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Chondrosarcomas are malignant bone tumors characterized by cartilaginous matrix production.
• Mutations in isocitrate dehydrogenase enzymes (IDH1/2) are found in various cancers, including chondrosarcomas, leading to the production of the oncometabolite D-2-hydroxyglutarate (D-2HG).
• The precise role of IDH mutations in chondrosarcoma tumorigenesis remains incompletely understood.

Purpose of the Study:

• To investigate the functional role of mutant IDH1 (IDH1mut) in chondrosarcoma development.
• To elucidate the molecular mechanisms by which IDH1mut contributes to chondrosarcoma progression.
• To identify potential therapeutic targets for IDH1mut-driven chondrosarcomas.

Main Methods:

• CRISPR/Cas9 gene editing was employed to knock out IDH1mut in chondrosarcoma cell lines.
• Assays were performed to measure D-2HG production, anchorage-independent growth, and cell migration.
• A xenograft model was utilized to assess tumor formation in vivo.
• RNA-sequencing (RNA-Seq) was conducted to analyze gene expression changes.

Main Results:

• IDH1mut knockout significantly suppressed D-2HG production, anchorage-independent growth, and cell migration.
• Loss of IDH1mut markedly attenuated chondrosarcoma formation and D-2HG levels in a xenograft model.
• RNA-Seq revealed downregulation of integrin genes, including ITGA5 and ITGB5, in IDH1mut knockout cells.
• Integrin-mediated processes were identified as contributors to the tumorigenicity of IDH1-mutant chondrosarcoma cells.

Conclusions:

• IDH1mut knockout abrogates chondrosarcoma genesis by modulating integrin expression and function.
• Integrin molecules represent promising targets for combination therapies with IDH1mut inhibitors in chondrosarcomas harboring this mutation.